In vitro and in vivo study then confirmed that ponatinib is a potent inhibitor of CEL cells bearing wild-type (WT) or T674I FIP1L1-PDGFRα. The gene discussed is PDGFRA; the disease is Chronic Eosinophilic Leukemia, Not Otherwise Specified.